Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
3 clinical trials · Condition
◉ Watch Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
| Record | Firm | Date |
|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (NCT07166419) | Ohio State University Comprehensive Cancer Center | 2026-01-14 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921) | Fred Hutchinson Cancer Center | 2018-02-23 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (NCT02381548) | National Cancer Institute (NCI) | 2015-08-18 |
Track Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive automatically
Every clearance here is in the API, with alerts when new ones post.